|
1
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002.
|
|
2
|
Arkenau HT, Kefford R and Long GV:
Targeting BRAF for patients with melanoma. Br J Cancer.
104:392–398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chapman PB, Hauschild A, Robert C, et al:
Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hauschild A, Grob JJ, Demidov LV, et al:
Dabrafenib in BRAF-mutated metastatic melanoma: a
multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012.PubMed/NCBI
|
|
5
|
Long GV, Trefzer U, Davies MA, et al:
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant
melanoma metastatic to the brain (BREAK-MB): a multicentre,
open-label, phase 2 trial. Lancet Oncol. 13:1087–1095. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Flaherty KT, Infante JR, Daud A, et al:
Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee JH, Choi JW and Kim YS: Frequencies of
BRAF and NRAS mutations are different in histological
types and sites of origin of cutaneous melanoma: a meta-analysis.
Br J Dermatol. 164:776–784. 2011.
|
|
8
|
Bauer J, Buttner P, Murali R, et al:
BRAF mutations in cutaneous melanoma are independently
associated with age, anatomic site of the primary tumor, and the
degree of solar elastosis at the primary tumor site. Pigment Cell
Melanoma Res. 24:345–351. 2011. View Article : Google Scholar
|
|
9
|
Schlaak M, Bajah A, Podewski T, et al:
Assessment of clinical parameters associated with mutational status
in metastatic malignant melanoma: a single-centre investigation of
141 patients. Br J Dermatol. 168:708–716. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Long GV, Menzies AM, Nagrial AM, et al:
Prognostic and clinicopathologic associations of oncogenic
BRAF in metastatic melanoma. J Clin Oncol. 29:1239–1246.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Viros A, Fridlyand J, Bauer J,
Lasithiotakis K, Garbe C, Pinkel D and Bastian BC: Improving
melanoma classification by integrating genetic and morphologic
features. PLoS Med. 5:e1202008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Houben R, Becker JC, Kappel A, Terheyden
P, Brocker EB, Goetz R and Rapp UR: Constitutive activation of the
Ras-Raf signaling pathway in metastatic melanoma is associated with
poor prognosis. J Carcinog. 3:62004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ellerhorst JA, Greene VR, Ekmekcioglu S,
et al: Clinical correlates of NRAS and BRAF mutations
in primary human melanoma. Clin Cancer Res. 17:229–235. 2011.
|
|
14
|
Safaee Ardekani G, Jafarnejad SM, Tan L,
Saeedi A and Li G: The prognostic value of BRAF mutation in
colorectal cancer and melanoma: a systematic review and
meta-analysis. PLoS One. 7:e470542012.
|
|
15
|
Nagore E, Requena C, Traves V, Guillen C,
Hayward NK, Whiteman DC and Hacker E: Prognostic value of BRAF
mutations in localized cutaneous melanoma. J Am Acad Dermatol. Jan
2–2014.(Epub ahead of print). View Article : Google Scholar
|
|
16
|
Balch CM, Gershenwald JE, Soong SJ, et al:
Final version of 2009 AJCC melanoma staging and classification. J
Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saint-Jean M, Quereux G, Nguyen JM, et al:
Is a single BRAF wild-type test sufficient to exclude melanoma
patients from vemurafenib therapy? J Invest Dermatol.
134:1468–1470. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
19
|
Jarry A, Masson D, Cassagnau E, Parois S,
Laboisse C and Denis MG: Real-time allele-specific amplification
for sensitive detection of the BRAF mutation V600E. Mol Cell
Probes. 18:349–352. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Menzies AM, Haydu LE, Visintin L, et al:
Distinguishing clinicopathologic features of patients with V600E
and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res.
18:3242–3249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shinozaki M, Fujimoto A, Morton DL and
Hoon DS: Incidence of BRAF oncogene mutation and clinical
relevance for primary cutaneous melanomas. Clin Cancer Res.
10:1753–1757. 2004.
|
|
22
|
Moreau S, Saiag P, Aegerter P, et al:
Prognostic value of BRAFV600 mutations in
melanoma patients after resection of metastatic lymph nodes. Ann
Surg Oncol. 19:4314–4321. 2012.
|
|
23
|
Colombino M, Capone M, Lissia A, et al:
BRAF/NRAS mutation frequencies among primary tumors and
metastases in patients with melanoma. J Clin Oncol. 30:2522–2529.
2012. View Article : Google Scholar
|
|
24
|
Lin J, Goto Y, Murata H, Sakaizawa K,
Uchiyama A, Saida T and Takata M: Polyclonality of BRAF mutations
in primary melanoma and the selection of mutant alleles during
progression. Br J Cancer. 104:464–468. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilmott JS, Tembe V, Howle JR, et al:
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF
inhibitor-resistant melanoma: a case illustrating the challenges
for personalized medicine. Mol Cancer Ther. 11:2704–2708. 2012.
|
|
26
|
Yancovitz M, Litterman A, Yoon J, et al:
Intra- and inter-tumor heterogeneity of
BRAFV600E mutations in primary and
metastatic melanoma. PLoS One. 7:e293362012. View Article : Google Scholar : PubMed/NCBI
|
